Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay

2026/02/01 by Jamie Feng, Sameena Khan, Thomas K. Waddell +33 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Genomics and Diagnostics #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations

paper · pdf · doi:10.1016/j.jtho.2026.103645

crossref issued 2026/02/01 · crossref published 2026/02/01 · crossref published-print 2026/02/01 · openalex publication_date 2026/02/01 · crossref created 2026/02/21 · openalex created_date 2026/02/22 · crossref deposited 2026/05/23 · crossref indexed 2026/05/23 · openalex updated_date 2026/06/19

Citations

• The Eighth Edition Lung Cancer Stage Classification

Discussions

• Our new study found that a ctDNA blood test could help identify which patients with early-stage lung cancer (stage I non-small cell lung cancer, NSCLC) are at higher risk of their cancer returning aft [bsky, 2 points, 0 comments]